Expression of melanoma-associated antigens in human dendritic cells pulsed with an interleukin-2 gene encoded vaccinia melanoma oncolysate (rIL-2VMO)

Dendritic cells (DCs) possess the unique abilities to initiate a primary immune response and to present antigens to naïve T lymphocytes. Recently, there has been a rapidly growing interest in the use of DCs in active specific immunotherapy (ASI) for the treatment of patients with cancer. In the present study, we determined the ability of DCs to express Melanoma-Associated Antigens (MAAs) from a polyvalent Melanoma Vaccine (DC-MelVac; Patent# 11221/5) developed in our facility. The vaccine consists of a recombinant IL-2 gene-encoded vaccinia melanoma oncolysate (rIL-2VMO) derived from an established human melanoma cell line. Our results show that r-IL2VMO-pulsed DCs express MAAs presented by the Mel-2 melanoma cell line oncolysate used in this study. We believe that these promising results will prove useful as an active specific immunotherapeutic agent for patients with Stage III melanoma.

• Publication year

  2006

• Venue

  Cancer Biology & Therapy

• Publication date

  2006-12-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cbt.5.12.3375PMID 17106244PMCID 9491305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy of tumor-bearing mice utilizing virus help

  2004cited by this paper
• Immunotherapy of malignant melanoma.

  2003cited by this paper
• Managing toxicities of high-dose interleukin-2.

  2002cited by this paper
• Dendritic cells (II): Role and therapeutic implications in cancer.

  2001cited by this paper
• Dendritic cell lineage, plasticity and cross-regulation

  2001cited by this paper
• Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells.

  2000cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Vaccine therapy for malignant melanoma

  1996cited by this paper
• Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.

  1994cited by this paper
• Heat shock response to vaccinia virus infection

  1994cited by this paper
• Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model

  1994cited by this paper
• Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.

  1994cited by this paper
• Vaccinia virus infection induces a stress response that leads to association of Hsp70 with viral proteins

  1992cited by this paper
• Immunotherapy of malignant melanoma.

  1982cited by this paper

• Cancer Vaccines: Bench to Bedside

  2016cites this paper
• Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.

  2013cites this paper
• Genetically engineered Newcastle disease virus for malignant melanoma therapy

  2009cites this paper
• A influência do fator de crescimento endotelial vascular na maturação "in vitro" de células dendríticas derivadas de monócitos

  2008cites this paper